NSE: LAURUSLABS | BSE: 540222

Expensive Performer

Download real time

601.40 -5.95 (-0.98%)

56.03% Gain from 52W Low

715.0K NSE+BSE Volume

NSE 20 May, 2025 1:56 PM (IST)

32,430.6

Market Cap

High in industry

1.2

Beta 1Year

High Volatility

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Laurus Labs Ltd.

30 Apr 2020

601.40

-0.98%

Laurus Labs (BUY): Good beat; firm FY21 outlook target raised to Rs 630

Buy: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Laurus Labs reported a strong operational beat of 8%/20%/41% on sales/EBITDA/ PBT in Q4.

Laurus Labs Ltd. has an average target of 633.50 from 4 brokers.

Laurus Labs Ltd.

24 Mar 2020

601.40

-0.98%

First Light | India Strategy: Covid-19, Weekly Eco Wrap

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

India Strategy: Covid-19 - Market bottom elusive stick to select cash-rich stocks. Weekly Eco Wrap: COVID-19 cases jump, so does volatility

Laurus Labs Ltd. has gained 22.99% in the last 6 Months

Laurus Labs Ltd.

31 Jan 2020

601.40

-0.98%

Laurus Labs (BUY): Another good beat TP raised to Rs 510

Buy: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Laurus Labs reported a consecutive beat with best-ever Q3 EBITDA, led by strong operating leverage in formulations and higher gross margins.

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

28 Nov 2019

601.40

-0.98%

Laurus Labs (BUY): NDR takeaways

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

We recently hosted the management of Laurus Labs with investors. Overall, we found management's tone confident yet realistic.

Laurus Labs Ltd. is trading below its 30 day SMA of 610.1

Laurus Labs Ltd.

01 Nov 2019

601.40

-0.98%

Healthy formulation revenue, operating leverage drive earnings

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

ARV-API (-23% YoY) and Hep-C (-47% YoY), however, were weak. Product mix superior: Gross margin expanded 295bp YoY to 49.5%, led by the increased share of FDF sales. EBITDA margin too improved 385bp YoY to 19.3% (our estimate: 17%), led by a better product mix and lower opex (75bp YoY). EBITDA increased 51% YoY to INR1.4b (our estimate: INR1.1b). PAT doubled YoY to INR566m, driven by strong sales growth, superior margins and a lower tax rate. For 1HFY20, revenue/EBITDA/PAT were up 12%/34%/118% YoY to INR12.6b/INR2.3b/INR716m. Key concall highlights: (1) LAURUS has garnered mid-teen market share in...

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

01 Nov 2019

601.40

-0.98%

Laurus Labs (BUY): All-round beat formulations turn EBITDA positive; BUY

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Laurus Labs reported its best-ever EBITDA in Q2FY20 with a good topline beat, led by strong operating leverage in the formulation business and gross margin expansion.

Laurus Labs Ltd. is trading below its 30 day SMA of 610.1

Laurus Labs Ltd.

05 Aug 2019

601.40

-0.98%

Laurus Labs (1QFY20): Small hiccup, story is intact. Maintain BUY

Buy: Laurus Labs Ltd.

Target

HDFC Securities

Laurus is sitting on ~40% underutilized gross block (~Rs 0.9bn) spread across formulations, CRAMS and API segments. With a sharp jump witnessed in formulations and higher visibility of CRAMS orders for FY20, we are confident that the operating/ financial leverage story will unfold from FY20. Assuming formulations revenues/ EBITDA at US$ 85/ 25mn in FY21E, earnings are likely to grow 2.5x over FY19-21E. With all four ARV formulation approvals (TLD, TLE 400, TLE 600, TEE) in place by 1HFY21, addressing >US$ 1.2bn opportunity, the estimates could be breached easily. Maintain BUY. We maintain a BUY on Laurus despite poor operational performance in 1QFY20. After adjusting for lack of scale up in ARV APIs and buoyancy in formulation segment, we have cut our FY20/21E numbers by 5-8% to arrive at a TP of Rs 470/sh (18x FY21E EPS).

Laurus Labs Ltd. is trading below its 30 day SMA of 610.1

Laurus Labs Ltd.

05 Aug 2019

601.40

-0.98%

Laurus Labs (BUY): High opex offsets formulation positives; expect recovery in Q2

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Q1FY20 operational results were in line despite strong gross margin expansion.

Laurus Labs Ltd. has an average target of 633.50 from 4 brokers.

Laurus Labs Ltd.

15 Jul 2019

601.40

-0.98%

Laurus Labs (Annual Report Analysis): FY20: To start on a strong note. Maintain BUY

Buy: Laurus Labs Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 515 (18x FY21E EPS). For Laurus Labs, FY19 was a landmark year in which it finally commenced ARV formulations (TLD) supplies to the Global Fund (GF) and has started to reap from the Rs 6-7bn investments made over the years for this segment. The company also turned around its EBITDA margin from 15% in 1QFY19 to 17% in 4QFY19 after facing severe price hikes (~60%) in a key raw material for the ARV API EMT, and partially overcoming it by way of backward integration and alternate sourcing. Overall, it achieved 11% YoY revenue growth, while APAT declined 32% driven by a 450bps contraction in EBITDA margin.

Laurus Labs Ltd. is trading below its 30 day SMA of 610.1

Laurus Labs Ltd.

06 May 2019

601.40

-0.98%

Laurus Labs (4QFY19): Delivery has begun. Maintain BUY

Buy: Laurus Labs Ltd.

HDFC Securities

With buoyant 4QFY19 numbers, we remain constructive on Laurus and believe it is best-positioned to successfully transition into a formulations and CRAMS player. This will lead to improved profitability in the coming years, driven by better business mix and operating/financial leverage. Laurus entered the US$ 1.8bn ARV formulations market in FY19. In our view, it can capture at least 15% market share (in TLE/TEE/TLD), supported by one of the largest ARV API capacities. With formulations revenues/EBITDA at US$ 85/25mn in FY21E, earnings can triple over FY19-21E (on a soft base). We also expect a couple of big-ticket formulations launches in the US market by FY21, which can further boost profitability. We strongly believe the stock is ripe for healthy returns. We maintain a BUY on Laurus following a bumper (yet inline) 4QFY19. Our TP is unchanged at Rs 535/sh (18x FY21E EPS). The delivery has begun.

Laurus Labs Ltd. has gained 22.99% in the last 6 Months

Is Laurus Labs Ltd. worth buying?

1219 Votes:

Buy 79.57%

Sell 10.83%

Hold 9.6%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf